Aktienanalyse wird geladen …
ABT · NYSE · Pharmaceuticals · USA
101,29 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 44,33 Mrd. | 6,52 Mrd. | 3,72 $ | 1,75 Mrd. | 6,6 Mio · 0,4 % | 6,6 Mio · 0,4 % | 56,4 % | 14,7 % | 4,23 $ | 0,38 $ | 2,40 $ |
| 2024 | 41,95 Mrd. | 13,4 Mrd. | 7,64 $ | 1,75 Mrd. | 6,6 Mio · 0,4 % | 7,6 Mio · 0,4 % | 55,4 % | 32 % | 3,63 $ | 0,39 $ | 2,24 $ |
| 2023 | 40,11 Mrd. | 5,72 Mrd. | 3,26 $ | 1,75 Mrd. | 6,4 Mio · 0,4 % | 21,4 Mio · 1,2 % | 55,2 % | 14,3 % | 2,89 $ | 0,37 $ | 2,08 $ |
| 2022 | 43,65 Mrd. | 6,93 Mrd. | 3,91 $ | 1,76 Mrd. | 6,8 Mio · 0,4 % | 31,8 Mio · 1,8 % | 56,2 % | 15,9 % | 4,42 $ | 0,39 $ | 1,92 $ |
| 2021 | 43,08 Mrd. | 7,07 Mrd. | 3,94 $ | 1,79 Mrd. | 6,3 Mio · 0,4 % | 3,3 Mio · 0,2 % | 57 % | 16,4 % | 4,83 $ | 0,36 $ | — |
| 2020 | 34,61 Mrd. | 4,5 Mrd. | 2,50 $ | 1,79 Mrd. | 5,4 Mio · 0,3 % | 0,4 Mio · 0 % | 56,7 % | 13 % | 3,20 $ | 0,31 $ | — |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|
| Q1 2026 | 11,16 Mrd. | 1,08 Mrd. | 0,61 $ | 1,75 Mrd. | 9,7 % | 0,52 $ |
| Q4 2025 | 11,46 Mrd. | 1,78 Mrd. | 1,01 $ | 1,75 Mrd. | 15,5 % | 1,50 $ |
| Q3 2025 | 11,37 Mrd. | 1,64 Mrd. | 0,94 $ | 1,75 Mrd. | 14,5 % | 1,31 $ |
| Q2 2025 | 11,14 Mrd. | 1,78 Mrd. | 1,01 $ | 1,75 Mrd. | 16 % | 0,88 $ |
| Q1 2025 | 10,36 Mrd. | 1,33 Mrd. | 0,76 $ | 1,75 Mrd. | 12,8 % | 0,53 $ |
| Q4 2024 | 10,97 Mrd. | 9,23 Mrd. | 5,26 $ | — | 84,1 % | 1,23 $ |
| Q3 2024 | 10,64 Mrd. | 1,65 Mrd. | 0,94 $ | 1,75 Mrd. | 15,5 % | 1,23 $ |
| Q2 2024 | 10,38 Mrd. | 1,3 Mrd. | 0,74 $ | 1,75 Mrd. | 12,6 % | 0,81 $ |
NVST vs. ABT: Which Stock Is the Better Value Option?
Abbott (ABT) Registers a Bigger Fall Than the Market: Important Facts to Note
Abbott Laboratories (ABT) is Facing Segment Competition and Sluggish Nutrition Recovery
TDM Reagent Kit Market Forecasts Growth from $2.87B (2026) to $6.96B by 2032, Profiling Abbott, Roche, Danaher, Siemens Healthineers & Thermo Fisher
Is Abbott’s Digital Health Push and Formula Settlement Altering The Investment Case For Abbott (ABT)?
What Makes Abbott Laboratories (ABT) an Attractive Opportunity?
Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a broad range of medical devices, diagnostic systems, nutritional products, and branded generic medicines. Its portfolio spans cardiovascular care, diabetes management, electrophysiology, structural heart, neuromodulation, laboratory diagnostics, point-of-care testing, adult and pediatric nutrition, and established pharmaceuticals for international markets. Abbott serves hospitals, laboratories, healthcare providers, pharmacies, and consumers through products used in chronic disease management, clinical testing, and everyday nutrition. The company plays a significant role in the healthcare market by combining device technology, diagnostics, and nutrition into a diversified platform that supports patient care across multiple settings. Abbott Laboratories is headquartered in Abbott Park, Illinois, and operates with a global commercial footprint across numerous countries.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest ABT und jede andere Aktie unbegrenzt.